New central government trade rules prohibit importing pharmaceutical products with remaining shelf life under twelve months

The central administration has officially blocked the commercial import of any pharmaceutical products that retain less than a full year of shelf life remaining at the time of entry. This trade restriction applies directly to foreign drug manufacturers, medical distributors, and local importers looking to bring pharmaceutical inventory across national borders. The regulatory mechanism governing drug imports is designed to prevent the accumulation of near-expiry medical stock and ensure consumer safety through adequate product stability windows.

In practice, businesses accustomed to bringing in shorter-dated clearance stock or discounted near-expiry inventory can no longer do so, shifting the burden entirely onto manufacturers to ship fresher batches. While previous import norms allowed greater flexibility for certain medical shipments, the new standard draws a strict line at the twelve-month remaining shelf life threshold for all incoming consignments. Professionals and supply chain managers must immediately audit existing purchase orders, verify manufacturing dates with overseas suppliers, and align upcoming import schedules with the twelve-month rule to prevent customs detentions.

Stakeholders should track upcoming customs circulars for potential procedural clarifications or conditional exemptions on orphan drugs and specialized therapies. Ultimately, maintaining strict batch-date verification will protect businesses from costly border rejections and regulatory penalties.